MA48793A - Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 - Google Patents

Procédés de fabrication et d'utilisation d'inhibiteurs de pde9

Info

Publication number
MA48793A
MA48793A MA048793A MA48793A MA48793A MA 48793 A MA48793 A MA 48793A MA 048793 A MA048793 A MA 048793A MA 48793 A MA48793 A MA 48793A MA 48793 A MA48793 A MA 48793A
Authority
MA
Morocco
Prior art keywords
manufacturing
methods
pde9 inhibitors
pde9
inhibitors
Prior art date
Application number
MA048793A
Other languages
English (en)
Inventor
Yuyin Chen
Jianshe Kong
Rujian Ma
Xiao Meng
Liang Qin
Fenglai Sun
Jikui Sun
Jinxu Sun
Niels Svenstrup
Huanming Xiao
Jun Zhang
Junhua Zhang
Jingyang Zhu
Original Assignee
Imara Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imara Inc filed Critical Imara Inc
Publication of MA48793A publication Critical patent/MA48793A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
MA048793A 2017-05-26 2018-05-25 Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 MA48793A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762511367P 2017-05-26 2017-05-26

Publications (1)

Publication Number Publication Date
MA48793A true MA48793A (fr) 2020-04-08

Family

ID=64396048

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048793A MA48793A (fr) 2017-05-26 2018-05-25 Procédés de fabrication et d'utilisation d'inhibiteurs de pde9

Country Status (19)

Country Link
US (2) US11370795B2 (fr)
EP (1) EP3630772B1 (fr)
JP (1) JP2020527535A (fr)
KR (1) KR102627975B1 (fr)
CN (2) CN111183140B (fr)
BR (1) BR112019024877A2 (fr)
CA (1) CA3064004A1 (fr)
DK (1) DK3630772T3 (fr)
EA (1) EA201992721A1 (fr)
FI (1) FI3630772T3 (fr)
HR (1) HRP20240146T1 (fr)
IL (1) IL270792B2 (fr)
LT (1) LT3630772T (fr)
MA (1) MA48793A (fr)
MX (2) MX2019014049A (fr)
PT (1) PT3630772T (fr)
RS (1) RS65143B1 (fr)
TW (2) TWI791021B (fr)
WO (1) WO2018218104A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865484B1 (fr) 2015-07-07 2023-11-08 H. Lundbeck A/S Inhibiteur de pde9 présentant un squelette d'imidazo pyrazinone pour le traitement de maladies périphériques
CN111183140B (zh) 2017-05-26 2022-12-02 伊马拉公司 制备和使用pde9抑制剂的方法
CN109734653B (zh) * 2019-02-21 2020-07-14 北京悦康科创医药科技股份有限公司 一种阿加曲班起始原料异构体杂质的拆分方法
WO2020202183A1 (fr) * 2019-03-29 2020-10-08 Mylan Laboratories Limited Procédé de préparation d'upadacitinib et de ses intermédiaires
CN114302724A (zh) * 2019-04-05 2022-04-08 伊马拉公司 用于治疗镰状细胞病的pde9抑制剂
WO2022036111A1 (fr) * 2020-08-13 2022-02-17 Imara Inc. Méthodes et compositions pour le traitement de la maladie à hématies falciformes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519300T2 (de) 1994-08-08 2001-05-31 Debiopharm Sa Stabiles arzneimittel enthaltend oxaliplatin
EP1368022B1 (fr) 2001-03-02 2007-06-20 Debiopharm S.A. Utilisation d'un flacon contenant une solution d'oxaliplatine
JP2005508978A (ja) * 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Pde9阻害薬によるインスリン抵抗性症候群及び2型糖尿病の治療
US7326421B2 (en) 2002-10-21 2008-02-05 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
NZ580904A (en) 2007-05-11 2012-02-24 Pfizer Amino-heterocyclic compounds for inhibiting pde9
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
EP2619208B1 (fr) 2010-09-20 2016-11-09 Ironwood Pharmaceuticals, Inc. Composés imidazotriazinones
MA37958B1 (fr) * 2011-10-10 2018-10-31 H Lundbeck As Pde9i ayant un squelette imidazo pyrazinone
EP3178820B1 (fr) * 2012-01-26 2017-12-20 H. Lundbeck A/S Inhibiteurs de pde9 avec squelette triazinone imidazo
WO2013170069A1 (fr) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Médicament, méthode, et dispositif d'administration de médicament pour le traitement du cancer de l'ovaire
PL2890384T3 (pl) 2012-08-31 2022-02-14 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę
EP2983730B1 (fr) 2013-04-10 2019-10-16 Massachusetts Institute of Technology Dispositifs et procédés d'administration de médicament locale pour traiter un cancer
US10369340B2 (en) 2013-08-12 2019-08-06 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
EP3865484B1 (fr) 2015-07-07 2023-11-08 H. Lundbeck A/S Inhibiteur de pde9 présentant un squelette d'imidazo pyrazinone pour le traitement de maladies périphériques
CN111183140B (zh) 2017-05-26 2022-12-02 伊马拉公司 制备和使用pde9抑制剂的方法

Also Published As

Publication number Publication date
PT3630772T (pt) 2024-02-05
MX2023000191A (es) 2023-02-09
US20200157108A1 (en) 2020-05-21
RS65143B1 (sr) 2024-02-29
TWI791021B (zh) 2023-02-01
MX2019014049A (es) 2020-07-28
CN111183140A (zh) 2020-05-19
FI3630772T3 (fi) 2024-01-31
CN115746003A (zh) 2023-03-07
DK3630772T3 (da) 2024-02-05
IL270792B2 (en) 2024-01-01
EP3630772A4 (fr) 2021-01-13
IL270792A (en) 2020-01-30
LT3630772T (lt) 2024-02-26
WO2018218104A1 (fr) 2018-11-29
BR112019024877A2 (pt) 2020-06-09
KR102627975B1 (ko) 2024-01-19
EA201992721A1 (ru) 2020-09-10
TW201908319A (zh) 2019-03-01
CN111183140B (zh) 2022-12-02
US20230183244A1 (en) 2023-06-15
EP3630772B1 (fr) 2023-11-01
HRP20240146T1 (hr) 2024-04-12
US11370795B2 (en) 2022-06-28
EP3630772A1 (fr) 2020-04-08
TW202334156A (zh) 2023-09-01
CA3064004A1 (fr) 2018-11-29
JP2020527535A (ja) 2020-09-10
IL270792B1 (en) 2023-09-01
KR20200016891A (ko) 2020-02-17

Similar Documents

Publication Publication Date Title
MA43802A (fr) Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci
MA48793A (fr) Procédés de fabrication et d'utilisation d'inhibiteurs de pde9
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA50077A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA48772A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
DK3710439T3 (da) Kras g12c-hæmmere
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA45779A (fr) Polypeptides immunomdulateurs et compositions et procédés associés
MA41613A (fr) Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
MA45094A (fr) Matériaux souples antidérapants et procédés pour leur fabrication et leur utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
ZA202002172B (en) Pde9 inhibitor and use thereof